Fintech

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Globenewswire·April 17, 2026 at 11:00 AM

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

Loop raises $95 million for supply chain data
PYMNTS
Cursor seeks $50B valuation amid AI coding demand
PYMNTS
Commercial Lending Boosts Regional Banks Amid Slowdown
PYMNTS
Judge rules Jenner memecoin not a security
The Block

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Loop raises $95 million for supply chain data

Cursor seeks $50B valuation amid AI coding demand

Commercial Lending Boosts Regional Banks Amid Slowdown

Judge rules Jenner memecoin not a security